# Toni Choueiri
פרקי פודקאסט מובילים
מְעוּדכָּן:
Toni K. Choueiri is a Lebanese American medical oncologist and researcher. He is the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School and Director of the Lank Center for Genitourinary Oncology at the Dana–Farber Cancer Institute. His work has led to the establishment of several novel drugs (cabozantinib, avelumab, pazopanib and others including combinations) and prognostic factors in advanced renal cell carcinoma (RCC).
Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC
Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.
GU ASCO 2025 Highlights - TALAPRO-2, NIAGARA, CheckMate-9ER, TiNivo-2
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Toni Choueiri, a leading GU medical oncologist from Dana-Farber Cancer Institute. Together, they dive into the highlights from the GU ASCO 2025 conference, covering key studi…
Episode 219: Major Progress in Adjuvant Renal Cell Carcinoma
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also cove…
Episode 423: ASCO 2025 - Casdatifan plus Cabo in refractory RCC
Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.
Kidney Cancer Findings from ASCO-GU, Dos & Don’ts in Reporting a Colleague
Toni Choueiri, MD (Dana-Farber Cancer Institute, Harvard), discusses the latest research in kidney cancer presented at the 2023 ASCO Genitourinary Cancers Symposium. Also, regular contributor Dr. MedLaw explains all you need to consider and do, as well as not do, in the delicate situation of havin…
ESMO 2022 Daily Round-Ups: Day 4
Catch up on our highlights from Day 4 of ESMO 2022!
We spoke to Toni Choueiri, Erika Hamilton, Jonathan Rosenberg, and Charles Swanton, among many more! Keep an eye on VJOncology for more interviews, podcasts, and roundtable discussions throughout the congress.
Management of Metastatic Renal Clear Cell Cancer Rapid Recommendation Update
Dr. Eric Singer highlights the recent rapid recommendation update from ASCO on the management of metastatic renal cell cancer (ccRCC), based on the review of evidence from the phase III COSMIC 313 trial. Dr. Singer reviews the discussion from the Expert Panel and emphasizes clinicians should conti…
Day 3: Top Takeaways From ASCO25
Dr. John Sweetenham shares highlights from Day 3 of the 2025 ASCO Annual Meeting, including new research for the treatment of advanced renal cell carcinoma and 2 studies on novel approaches in non-small cell lung cancer. Transcript
Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of …
Key Advances in Prostate, Kidney, and Bladder Cancers at GU24
Drs. Neeraj Agarwal and Todd Morgan discuss CONTACT-02, KEYNOTE-564, CheckMate-67T, and other notable studies featured at the 2024 ASCO Genitourinary Cancers Symposium, as well as additional key abstracts in prostate, kidney, and bladder cancers that will significantly influence clinical practice.…
Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates
Toni Choueiri joins Brian and Tom to discuss a recent Nature paper regarding the novel HIF inhibitor, casdatifan, and biomarkers of response.
מנוע חיפוש PODCAST
אתה יכול להשתמש באתר שלנו כדי לחפש3,823,979פודקאסטים ופודקאסטים195,701,402לפי אנשים, מקומות או נושאים.
השקעה בידע מניבה את התשואה הטובה ביותר, ולכן אני מאזין לפודקאסטים.
‐ Benjamin "Llamacorn" Franklin
